University of Wollongong

Research Online
Faculty of Science, Medicine and Health - Papers

Faculty of Science, Medicine and Health

2004

Oxaliplatin, fluorouracil, and leucovorin as adjuvant
treatment for colon cancer
Thierry Andre
Hopital Tenon, Paris

Corrado Boni
Arcispedale Santa Maria Nuova

Lamia Mounedji-Boudiaf
Sanofi-Synthelabo

Matilde Navarro
Hospital Duran i Reynals

Josep Tabernero
Vall d'Hebron University Hospital
See next page for additional authors

Publication Details
Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater,
J., Tabah-Fisch, I. & de Gramont, A. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New
England Journal of Medicine, 350 (23), 2343-2351.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon
cancer
Abstract

BACKGROUND: The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL).
Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We
evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. METHODS:
We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to
receive FL alone or with oxatiplatin for six months. The primary end point was disease-free survival.
RESULTS: A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9
months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with
293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The
rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in
the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL
group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile
neutropenia was 1.8 percent, the incidence of gastro-intestinal adverse effects was low, and the incidence of
grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of followup. Six patients in each group died during treatment (death rate, 0.5 percent). CONCLUSIONS: Adding
oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
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Oxaliplatin, Fluorouracil, and Leucovorin
as Adjuvant Treatment for Colon Cancer
Thierry André, M.D., Corrado Boni, M.D., Lamia Mounedji-Boudiaf, M.D.,
Matilde Navarro, M.D., Josep Tabernero, M.D., Tamas Hickish, M.D.,
Clare Topham, M.D., Marta Zaninelli, M.D., Philip Clingan, M.D.,
John Bridgewater, M.D., Isabelle Tabah-Fisch, M.D.,
and Aimery de Gramont, M.D., for the Multicenter International Study
of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment
of Colon Cancer (MOSAIC) Investigators

abstract
background

The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL).
Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the
postoperative adjuvant setting.
methods

We randomly assigned 2246 patients who had undergone curative resection for stage II
or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary
end point was disease-free survival.
results

A total of 1123 patients were randomly assigned to each group. After a median followup of 37.9 months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1
percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at
three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group
given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7)
in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was
12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six
patients in each group died during treatment (death rate, 0.5 percent).

From Hôpital Tenon, Paris (T.A.);
GERCOR Oncology Multidisciplinary
Group, Paris (T.A., A.G.); Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
(C.B.); Sanofi-Synthelabo, Paris (L.M.-B.,
I.T.-F.); Hospital Duran i Reynals, l’Hospitalet de Llobregat, Llobregat, Spain (M.N.);
Vall d’Hebron University Hospital, Barcelona, Spain (J.T.); Dorset Cancer Centre,
Royal Bournemouth and Poole Hospitals,
Bournemouth, United Kingdom (T.H.); Royal Surrey County Hospital, Guildford, Surrey, United Kingdom (C.T.); Ospedale Borgotrento, Verona, Italy (M.Z.); Southern
Medical Day Care Centre, Wollongong, Australia (P.C.); North Middlesex Hospital,
London (J.B.); and Hôpital Saint-Antoine,
Paris (A.G.). Address reprint requests to
Dr. de Gramont at Hôpital Saint Antoine,
184 rue du Faubourg Saint Antoine, Paris
75012, France, or at aimery.de-gramont@
sat.ap-hop-paris.fr.
N Engl J Med 2004;350:2343-51.
Copyright © 2004 Massachusetts Medical Society.

conclusions

Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant
treatment of colon cancer.
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olorectal cancer is the second
leading cause of death from cancer in
Western countries1; 40 to 50 percent of patients who undergo potentially curative surgery
alone ultimately relapse and die of metastatic disease.2 The most important prognostic indicator of
survival in early colon cancer is the stage of the tumor (T, according to the tumor–node–metastasis
[TNM] classification), determined by the depth of
penetration through the bowel wall, and the number of involved lymph nodes.3
The demonstration that postoperative adjuvant
treatment with fluorouracil and levamisole reduced
the mortality rate by 33 percent among patients
with stage III colon cancer 4 prompted several trials,
which established six months of treatment with
fluorouracil plus leucovorin (FL) as the standard adjuvant chemotherapy for stage III colon cancer.5-11
Oxaliplatin is a third-generation platinum derivative, which, when combined with fluorouracil and
leucovorin, is among the most effective chemotherapies for metastatic colorectal cancer.12-15 To
determine whether oxaliplatin can also benefit patients with disease in an earlier stage, we conducted an international phase 3 clinical trial in patients
with stage II or III colon cancer — the Multicenter
International Study of Oxaliplatin/5-Fluorouracil/
Leucovorin in the Adjuvant Treatment of Colon
Cancer (MOSAIC).

methods
patients

of

medicine

treatment

Eligible patients were randomly assigned to receive
FL alone or with oxaliplatin. In the FL group, each
cycle comprised a 2-hour infusion of 200 mg of leucovorin per square meter of body-surface area followed by a bolus of 400 mg of fluorouracil per
square meter and then a 22-hour infusion of 600
mg of fluorouracil per square meter given on 2 consecutive days every 14 days, for 12 cycles. In the
group given FL plus oxaliplatin, the same FL regimen was used, plus a two-hour infusion of 85 mg
of oxaliplatin (Eloxatin, Sanofi-Synthelabo) per
square meter on day 1, given simultaneously with
leucovorin, with the use of a Y infusion device. The
use of disposable pumps (LV5 infusors, Baxter
Healthcare) allowed outpatients to receive a continuous infusion of fluorouracil.
Adverse effects were graded according to the
Common Toxicity Criteria of the National Cancer
Institute, version 1. According to these criteria, a
score of 1 indicates mild adverse effects, a score of
2 moderate adverse effects, a score of 3 severe adverse effects, and a score of 4 life-threatening adverse effects. Dose reductions were based on the
worst adverse effects observed during the previous
cycle. The dose of oxaliplatin was to be reduced to
75 mg per square meter in the event of persistent
(at least 14 days) paresthesias, temporary painful
paresthesias, or functional impairment. Oxaliplatin was discontinued in cases of persistent painful
paresthesias or functional impairment. Together
with reductions in the dose of oxaliplatin, the bolus
dose of fluorouracil was reduced to 300 mg per
square meter and the infusion to 500 mg per
square meter in the event of grade 3 or 4 neutropenia or thrombocytopenia (or both), diarrhea, stomatitis, or other drug-related adverse effects of
grade 3. Only the dose of fluorouracil was scheduled to be reduced in the event of skin-related adverse effects of grade 3 or 4. Treatment was delayed
by up to three weeks until the patient recovered
from various adverse effects, the neutrophil count
exceeded 1500 per cubic millimeter, and the platelet count exceeded 100,000 per cubic millimeter.
Chemotherapy was stopped in the event of cardiac
or neurocerebellar adverse effects or grade 3 or 4 allergic reactions.

Patients were eligible if they had undergone complete resection of histologically proven stage II (T3
or T4,N0,M0) or stage III (any T,N1 or N2,M0) colon cancer, as defined by the presence of the inferior pole of the tumor above the peritoneal reflection
— that is, at least 15 cm from the anal margin.
Treatment had to be started within seven weeks after surgery. Other eligibility criteria included an age
of 18 to 75 years; a Karnofsky performance-status
score of at least 60; a carcinoembryonic antigen
level of less than 10 ng per milliliter; the absence of
prior chemotherapy, immunotherapy, or radiotherapy; and adequate blood counts and liver and
kidney function. Written informed consent was required from all patients, and the study was approved by the ethics committees of the participat- follow-up
Patients were assessed before randomization, eving centers.
ery two weeks during treatment, and then every six
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months for five years. The baseline assessment
involved a medical history taking, physical examination, biologic tests, measurement of the carcinoembryonic antigen level, chest radiography, and
abdominal ultrasonography or computed tomography. Patients were monitored for adverse effects
throughout the treatment period and until 28 days
after the last cycle of chemotherapy, unless treatment-related adverse effects required additional
follow-up.
The diagnosis of recurrence was made on the
basis of imaging and, if necessary, cytologic analysis
or biopsy. An elevated carcinoembryonic antigen
level as a solitary finding was not accepted as evidence of relapse. Neurologic adverse effects were to
be reported at each visit during follow-up and were
assessed with the use of the neurosensory section
of the Common Toxicity Criteria of the National
Cancer Institute, version 1.

ment on disease-free survival across prognostic
subgroups, we calculated hazard ratios and 95 percent confidence limits for subgroups defined according to the following variables: sex, age, disease
stage (II vs. III), baseline serum carcinoembryonic antigen level, number of involved lymph nodes
(≤4 vs. >4), T classification (T4 vs. T1, T2, or T3),
degree of cellular differentiation (well vs. poorly
differentiated), and the presence or absence of perforation, obstruction, and venous invasion.
The cutoff date of the analysis was April 22,
2003. The duration of follow-up was defined as the
number of months from randomization to the cutoff date.
Secondary end points were safety, including
long-term adverse effects, and overall survival, measured from the time of randomization to death from
any cause. With a median follow-up of three years,
it is too early to compare the two treatment groups
statistically in terms of survival, and only descripstatistical analysis
tive analyses of overall survival are presented. SafeRandomization was performed centrally, and the ty analyses included patients who had received at
minimization method was used to balance treat- least one cycle of treatment.
ment allocation according to the TNM stage (T2 or
T3 vs. T4 and N0, N1, or N2), the presence or ab- organization of the trial
sence of bowel obstruction or tumor perforation, The concept underlying this study was developed
and the medical center. The sample size of 2200 by Dr. de Gramont, and the investigation was depatients was calculated under the assumptions of a signed by the investigators and Sanofi-Synthelabo.
three-year disease-free survival rate of 73 percent in Data were collected, managed, and analyzed by the
the control group and 79 percent in the group giv- sponsor. The article was written by the investigaen FL plus oxaliplatin, with a ratio of stage II dis- tors, on the basis of data and statistical analyses
ease to stage III disease of 0.4:0.6, an enrollment provided by Sanofi-Synthelabo.
period and a follow-up period of three years, a deA data and safety monitoring board of indepencrease in the risk of relapse after three years, a sta- dent experts reviewed safety data every six months
tistical power of 90 percent, and an alpha value of during the treatment period to provide the sponsor
0.05 and two-sided P values derived with the use of with independent advice on the progress of the
the log-rank test. The primary efficacy variable was study and on safety. No interim analysis was
disease-free survival, defined as the time from ran- planned or performed.
domization to relapse or death, whichever occurred
first. Second colorectal cancers were considered
results
relapses, whereas noncolorectal tumors were disstudy population
regarded in the analyses.
The primary statistical analysis of efficacy was Between October 1998 and January 2001, 2246 pathe comparison, after three years of follow-up, of tients were enrolled at 146 centers in 20 countries:
disease-free survival between groups according to 1123 patients were randomly assigned to receive
the intention-to-treat principle, with the use of a FL plus oxaliplatin and 1123 to receive FL without
two-sided log-rank test stratified according to base- oxaliplatin. Of these patients, 1108 received at least
line disease stage. Hazard ratios and 95 percent con- one cycle of FL plus oxaliplatin and 1111 received
fidence intervals were calculated with the use of the at least one cycle of FL. The patients’ characteristics
Cox proportional-hazards model. Survival curves were well matched in the two groups (Table 1). In
were drawn according to Kaplan–Meier methods. both groups, 60 percent of the patients had stage
To assess the consistency of the effect of treat- III disease and 40 percent had stage II disease. The
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Table 1. Baseline Characteristics of the Patients in the Group Given
Fluorouracil and Leucovorin (FL) plus Oxaliplatin and the FL Group.
Characteristic

FL plus Oxaliplatin
FL
(N=1123)
(N=1123)

All patients
Age — yr
Median

61

60

Range

19–75

20–75

723 (64.4)

743 (66.2)

Male

630 (56.1)

588 (52.4)

Female

493 (43.9)

535 (47.6)

5 (0.4)

5 (0.4)

Age <65 yr — no. (%)
Sex — no. (%)

Karnofsky performance-status score — no. (%)
<60
60–70

150 (13.4)

134 (11.9)

80–100

968 (86.2)

984 (87.6)

Disease stage — no. (%)
II

451 (40.2)

448 (39.9)

III

672 (59.8)

675 (60.1)

T2

51 (4.5)

54 (4.8)

T3

853 (76.0)

852 (75.9)

T4

213 (19.0)

208 (18.5)

6 (0.5)

9 (0.8)

201 (17.9)

217 (19.3)

78 (6.9)

78 (6.9)

Well differentiated

934 (83.2)

914 (81.4)

Poorly differentiated

142 (12.6)

148 (13.2)

47 (4.2)

61 (5.4)

Depth of invasion — no. (%)

Unknown
Bowel obstruction — no. (%)
Perforation — no. (%)
Histologic appearance — no. (%)

Unknown

of

medicine

overall median time between surgery and the start
of chemotherapy was 5.7 weeks (range, 1.1 to 17.0).
A total of 41 patients (1.8 percent) did not
strictly meet eligibility criteria related to baseline
disease. In one patient in each group, the resection
of primary tumor was incomplete. Four patients in
the group given FL plus oxaliplatin and six in the FL
group had a history of cancer, including colorectal
cancer. Thirteen patients (four in the group given
FL plus oxaliplatin and nine in the FL group) had
stage IV cancer, and three patients (two in the group
given FL plus oxaliplatin and one in the FL group)
had cancer of the middle or lower rectum. Four patients in the group given FL plus oxaliplatin and
nine in the FL group had various other eligibilitycriteria violations.
chemotherapy

The median number of cycles of chemotherapy received was 12 in both groups; 74.7 percent of patients in the group given FL plus oxaliplatin and
86.5 percent in the FL group received the planned
12 cycles. In the group that received FL plus oxaliplatin, the median dosage of oxaliplatin was 34.2
mg per square meter per week across all cycles received and 36.5 mg per square meter per week
across cycles including oxaliplatin. In both cases,
more than 80 percent of the planned dose was actually given (80.5 percent and 85.9 percent, respectively). The dose of fluorouracil received was 84.4
percent of the planned dose in the group given FL
plus oxaliplatin and 97.7 percent of the planned
dose in the FL group.

Patients with stage III disease — no. (%)

safety
No. of nodes involved
1–4

499 (44.4)

513 (45.7)

>4

170 (15.1)

160 (14.2)

2 (0.2)

2 (0.2)

84 (18.6)

87 (19.4)

Unknown
Patients with stage II disease — no. (%)
T4
No. of lymph nodes examined
<10

152 (33.7)

149 (33.3)

≥10

295 (65.4)

294 (65.6)

Bowel obstruction

71 (15.7)

87 (19.4)

Perforation

38 (8.4)

43 (9.6)

385 (85.4)

378 (84.4)

Histologic appearance
Well differentiated
Poorly differentiated

47 (10.4)

42 (9.4)

Unknown

19 (4.2)

28 (6.3)

2346
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Neutropenia, diarrhea, and vomiting were the most
frequent grade 3 or 4 adverse effects in the group
given FL plus oxaliplatin (Table 2). Grade 3 or 4
neutropenia was much commoner with FL plus oxaliplatin than with FL (41.1 percent vs. 4.7 percent,
P<0.001) but was complicated by fever or infection
in only 1.8 percent of cases (20 patients) in the
group given FL plus oxaliplatin and in 0.2 percent of
cases (2 patients) in the FL group (P<0.001). The
incidence of thromboembolic events among patients who received at least one cycle of the assigned regimen was similar in the two groups (63
of 1108 patients [5.7 percent] and 72 of 1111 patients [6.5 percent], respectively).
Although 92.1 percent of patients treated with FL
plus oxaliplatin had peripheral neuropathy during
treatment, half of these episodes were of grade 1
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Table 2. Adverse Events in the Group Given Fluorouracil and Leucovorin (FL) plus Oxaliplatin and the FL Group.*
Adverse Event

FL plus Oxaliplatin (N=1108)

FL (N=1111)

P Value

All Grades Grade 3 Grade 4

All Grades Grade 3 Grade 4

All Grades Grades 3 and 4

percent
Paresthesia†

92.0

12.4

NA

15.6

0.2

NA

<0.001

0.001

Neutropenia

78.9

28.8

12.3

39.9

3.7

1.0

<0.001

<0.001

Thrombocytopenia

77.4

1.5

0.2

19.0

0.2

0.2

<0.001

0.001

Anemia

75.6

0.7

0.1

66.9

0.3

0.0

<0.001

0.09

Nausea

73.7

4.8

0.3

61.1

1.5

0.3

<0.001

<0.001

Diarrhea

56.3

8.3

2.5

48.4

5.1

1.5

<0.001

<0.001

Vomiting

47.2

5.3

0.5

24.0

0.9

0.5

<0.001

<0.001

Stomatitis

41.6

2.7

0.0

39.6

2.0

0.2

0.34

0.41

Skin‡

31.5

1.4

0.6

35.5

1.7

0.7

0.05

0.67

Alopecia§

30.2

NA

NA

28.1

NA

NA

0.28

NA

Allergic reaction

10.3

2.3

0.6

1.9

0.1

0.1

<0.001

<0.001

Thrombosis
or phlebitis

5.7

1.0

0.2

6.5

1.7

0.1

0.48

0.29

Neutropenia with
fever or infection

1.8

1.4

0.4

0.2

0.1

0.1

<0.001

<0.001

* Fisher’s exact test was used to calculate P values. NA denotes not applicable.
† There are only three grades of paresthesia in version 1 of the Common Toxicity Criteria of the National Cancer Institute.
‡ This category included the hand–foot syndrome.
§ There are only two grades of alopecia in version 1 of the Common Toxicity Criteria of the National Cancer Institute. The
incidence of grade 2 alopecia was 5.0 percent in each group.

(Table 3). Of the 137 patients (12.4 percent) who
had grade 3 peripheral neuropathy during treatment, grade 3 symptoms were still present in 8 patients at the six-month follow-up visit and in 5 patients at the one-year visit. In 12 patients, grade 3
peripheral neurosensory symptoms appeared after
the end of treatment, and 6 of these patients had
persistent grade 3 symptoms after one year. In total,
11 of 1018 patients (1.1 percent) who were assessed
one year after the end of treatment continued to
have grade 3 peripheral neurosensory symptoms.
This number dropped to five (0.5 percent) after 18
months (Table 3).
Twelve patients — six in each group (0.5 percent) — died within 1 month after the end of treatment; these included three deaths in each group
during the first 60 days of treatment. In the group
given FL plus oxaliplatin, four patients died of infection or sepsis (two with neutropenia) and two of
intracranial hemorrhage. In the FL group, one patient each died of sepsis, Stevens–Johnson syndrome in the context of severe diarrhea and fluconazole treatment, and anoxic cerebral infarction;
one patient committed suicide; and two died suddenly from cardiac causes.

n engl j med 350;23

follow-up

There was good compliance with follow-up visits.
The mean time between visits was 5.97 months in
the group given FL plus oxaliplatin and 5.98 months
in the FL group. The median interval was 6.01
months in both groups.

Table 3. Incidence of Neurosensory Symptoms during Treatment
and Follow-up in the Group Given Fluorouracil, Leucovorin, and Oxaliplatin.*

Grade

During
Treatment
(N=1106)

1 Mo
Follow-up
(N=1092)

0

87 (7.9)

424 (38.8)

1

533 (48.2)

2
3

6 Mo
Follow-up
(N=1058)

12 Mo
Follow-up
(N=1018)

18 Mo
Follow-up
(N=967)

624 (59.0)

718 (70.5)

738 (76.3)

439 (40.2)

338 (31.9)

240 (23.6)

191 (19.8)

349 (31.6)

174 (15.9)

82 (7.8)

49 (4.8)

33 (3.4)

137 (12.4)

55 (5.0)

14 (1.3)

11 (1.1)

5 (0.5)

number (percent)

* Only patients who actually received treatment were included in the analysis.
A grade of 0 indicates no change or no symptoms, a grade of 1 mild paresthesia and loss of deep tendon reflexes, a grade of 2 mild or moderate objective
sensory loss and moderate paresthesia, and a grade of 3 severe objective sensory loss or paresthesias that interfere with function.
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disease-free survival

At the time of analysis (median follow-up, 37.9
months), 237 patients in the group given FL plus
oxaliplatin (21.1 percent) had relapsed or died, as
compared with 293 (26.1 percent) in the FL group.
Table 4. Analysis of Disease-free Survival According to the Intention-to-Treat
Principle.*
Variable

FL plus Oxaliplatin
(N=1123)

FL
(N=1123)

37.9
27–54

37.8
27–54

78.2 (75.6–80.7)

72.9 (70.2–75.7)

237 (21.1)
208 (18.5)
169 (15.0)
6 (0.5)
38 (3.4)

293 (26.1)
279 (24.8)
229 (20.4)
9 (0.8)
51 (4.5)

29 (2.6)

14 (1.2)

Follow-up — mo
Median
Range
Probability of disease-free survival
at 3 yr — % (95% CI)†
Event — no. (%)
Relapse‡
Metastasis
Second colorectal carcinoma
Local relapse
Death without relapse

* FL denotes fluorouracil and leucovorin, and CI confidence interval.
† P=0.002 by the stratified log-rank test for the comparison between groups.
‡ The same patient could have been counted in more than one relapse category
if several types of relapses were reported at the same follow-up visit.

1.0

Probability of Disease-free Survival

0.9

FL plus oxaliplatin (237 events, 21.1%)

medicine

The hazard ratio for recurrence in the group given
FL plus oxaliplatin, as compared with the FL group,
was 0.77 (P=0.002), corresponding to a 23 percent
reduction in the risk of relapse. The probability of
disease-free survival at three years was 78.2 percent
(95 percent confidence interval, 75.6 to 80.7 percent) in the group given FL plus oxaliplatin and
72.9 percent (95 percent confidence interval, 70.2
to 75.7 percent) in the FL group (P=0.002 by the
stratified log-rank test) (Table 4 and Fig. 1).
Among patients with stage III disease, the hazard ratio for relapse was 0.76 (95 percent confidence interval, 0.62 to 0.92) in the group given FL
plus oxaliplatin, as compared with the FL group,
and the three-year disease-free survival rate was
72.2 percent and 65.3 percent, respectively (Fig. 2).
Among patients with stage II disease, the hazard
ratio for relapse was 0.80 (95 percent confidence
interval, 0.56 to 1.15) in the group given FL plus
oxaliplatin, as compared with the FL group, and
the three-year disease-free survival rates were 87.0
percent and 84.3 percent, respectively (Fig. 2).
A Cox-model analysis showed that the reduced
risk of recurrence with FL plus oxaliplatin was similar in patients with stage II and those with stage III
disease (P=0.77). Calculation of hazard ratios and
95 percent confidence intervals (Fig. 3) showed
that the reduced risk of relapse was consistent in all
subgroups defined on the basis of prognostic factors at baseline.

0.8
0.7

overall survival

FL (293 events, 26.1%)

At the time of the cutoff date of the primary analysis, 133 patients had died in the group given FL
plus oxaliplatin, as compared with 146 patients in
the FL group (hazard ratio for death, 0.90; 95 percent confidence interval, 0.71 to 1.13), and the probability of survival at three years was 87.7 percent
and 86.6 percent, respectively. Most of the patients
who died had stage III disease (104 in the group
given FL plus oxaliplatin and 119 in the FL group);
the hazard ratio for death in this subgroup was
0.86 (95 percent confidence interval, 0.66 to 1.11).
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of
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1023
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959
903

888
817

discussion
Figure 1. Kaplan–Meier Estimates of Disease-free Survival in the Group Given Fluorouracil and Leucovorin (FL) and the Group Given FL plus Oxaliplatin,
According to the Intention to Treat.
The hazard ratio for recurrence in the group given FL plus oxaliplatin, as compared with the FL group, was 0.77 (95 percent confidence interval, 0.65 to
0.91; P=0.002).
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In previous trials, the addition of oxaliplatin to
fluorouracil and leucovorin doubled the response
rate and prolonged progression-free survival among
patients with metastatic colorectal cancer.14 The
efficacy and safety of this regimen were recently
confirmed in a large, randomized, phase 3 trial,

www.nejm.org

june 3 , 2004

The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSITY OF WOLLONGONG on August 5, 2013. For personal use only. No other uses without permission.
Copyright © 2004 Massachusetts Medical Society. All rights reserved.

oxaliplatin, fluorouracil, and leucovorin for colon cancer

Probability of Disease-free Survival
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Figure 2. Kaplan–Meier Estimates of Disease-free Survival in the Group Given Fluorouracil and Leucovorin (FL)
and the Group Given FL plus Oxaliplatin, According to the Stage of Disease and the Intention to Treat.

which found that this approach was superior (with
respect to all efficacy variables, including overall
survival) to the combination of irinotecan, fluorouracil (given as a bolus), and leucovorin.15 Our trial
was designed to test the efficacy of adjuvant treatment with the regimen of FL plus oxaliplatin. We
chose disease-free survival as the primary end
point of the study because, like others,16 we believe
that the absence of relapse is the best indicator of
efficacy, since it relates directly to the effect of the
treatment under investigation. By allowing early
appraisal of the results, the use of three-year disease-free survival as the primary end point for adjuvant trials of patients with colon cancer should permit rapid evaluation of new treatments. Whether
disease-free survival should be a primary end point
is still under discussion, but a recent analysis of
several studies supports the appropriateness of the
use of three-year disease-free survival as a good
predictor of five-year overall survival in trials of adjuvant treatment of colon cancer.17
Disease-free survival in the FL group in our
study falls within the highest range reported in
most studies of adjuvant treatment of colon cancer
with FL.6-8,18,19 The improvement in disease-free
survival among patients who were treated with FL
plus oxaliplatin corresponds to a relative reduction
in the risk of recurrence of 23 percent. Since most

n engl j med 350;23

relapses after curative surgery occur within the first
three years, we consider our results in this respect
to be complete.
Although it is agreed that patients with stage III
disease benefit from adjuvant treatment, whether
all patients with stage II disease should receive
such treatment remains debatable. This controversy was sustained for years by the contradictory conclusions of two large groups of investigators. The
National Surgical Adjuvant Breast and Bowel
Project concluded that the relative benefits of treatment were largely the same for stage II and stage
III tumors,20 whereas the International Multicentre Pooled Analysis of B2 Colon Cancer Trials
(IMPACT B2) failed to demonstrate a statistically
significant benefit for stage II tumors.21
A recent meta-analysis from the Mayo Clinic,22
which evaluated individual data on 3300 patients
who were enrolled in five randomized trials, including those analyzed in IMPACT B2, concluded
that patients with stage II disease could benefit
from adjuvant chemotherapy, but to a lesser extent
than patients with stage III tumors. Indeed, the absolute benefit among patients with stage II disease
is only half as great as that among patients with
stage III disease, and twice as many patients with
stage II tumors are required in such studies in order to detect a difference.
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A test for interaction is an appropriate statistical
approach to the question of whether the benefit of
adjuvant treatment differs between stage II and
stage III colorectal cancer.23 In our study, this test
showed no significant interaction between the stage
of disease and the treatment, indicating that FL
plus oxaliplatin benefited both stage II and stage

Prognostic Factor

Hazard Ratio (95% CI)

Overall
Sex
Male
Female
Age
≥65 yr
<65 yr
Tumor stage
T4
T1–T3
Nodal stage
N2
N0 or N1
Stage
III
II
Obstruction
Present
Absent
Perforation
Present
Absent
CEA after surgery
≥5 ng/ml
<5 ng/ml
Degree of differentiation
Well differentiated
Poorly differentiated
Venous invasion
Present
Absent
0.0

0.2

0.4

0.6

FL+Oxaliplatin
Better

0.8

1.0

1.2

1.4

1.6

1.8

FL Better

Figure 3. Hazard Ratios and 95 Percent Confidence Intervals for Recurrence
in the Group Given Fluorouracil and Leucovorin (FL) plus Oxaliplatin,
as Compared with the FL Group, According to Baseline Prognostic Factors
and the Intention to Treat.
CEA denotes carcinoembryonic antigen.
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III colorectal cancer. From a clinical standpoint,
stage II colon cancer occurs in a heterogeneous,
node-negative population in which clinical and biologic prognostic factors other than the status of
lymph-node involvement need to be taken into account. Tools are being developed to help physicians assess the risk–benefit ratio of adjuvant chemotherapies for individual patients.22
With no clear consensus on the most effective
FL regimen to be used for adjuvant treatment, we
chose a twice-monthly regimen because of its efficacy and low rates of adverse effects in patients
with advanced colorectal cancer, alone and in combination with oxaliplatin.12,14,24 Supporting our
decision are recent results demonstrating that this
approach to adjuvant therapy is less toxic than
monthly bolus injections of FL and is just as effective.18 This approach led to a straightforward study
design, since the treatment in both groups was
similar except for the addition of oxaliplatin in the
group given FL plus oxaliplatin. The improved disease-free survival in the FL-plus-oxaliplatin group
is thus directly linked to oxaliplatin.
The main safety concern regarding the use of
oxaliplatin is peripheral neuropathy. Oxaliplatin induces frequent, transient, distal paresthesias during or shortly after the first minutes of infusion. In
some cases these neurosensory symptoms increase
in intensity with cumulative doses, persist between
cycles, and interfere with function (in the case of
grade 3 effects).12,14,25 We observed grade 3 peripheral neuropathy in 12.4 percent of patients who
were receiving oxaliplatin. At one year, 11 patients
(1.1 percent) had grade 3 neuropathy. Among them,
two were found to have underlying disease that
could have caused these symptoms (diabetes and
hemiplegia, respectively). Although more frequent
among patients receiving FL plus oxaliplatin than
among those treated with FL alone, grade 3 or 4 neutropenia led to fever or infection in only 1.8 percent
of patients in the former group. Similar findings
have been reported among patients with metastatic colorectal cancer.14 From a safety standpoint,
the rate of death from any cause was similarly low
during treatment in both groups and, at 0.5 percent, is among the lowest figures reported in trials
of adjuvant chemotherapy.5,18,26,27
Figures for overall survival at this stage of the
study are preliminary, and no conclusion can be
drawn about differences in survival between the
treatment groups. Since the median overall survival from the time of diagnosis of metastatic colorec-
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tal cancer is approximately 20 months,13-15,28 we
expect that the effect of oxaliplatin on survival will
become apparent within the next 2 years.
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